These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38024490)

  • 1. Drug Pricing of Domestic Anti-PD-L1 Antibody Adebrelimab: Cost-Effectiveness Analysis of the First-Line ES-SCLC Treatment in China.
    Zhou D; Dong X; Zhou Z; Liu Q
    Risk Manag Healthc Policy; 2023; 16():2521-2529. PubMed ID: 38024490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing.
    Gan Y; Shi F; Zhu H; Han S; Li D
    Front Pharmacol; 2023; 14():1241130. PubMed ID: 37547339
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer.
    You M; Chen R; Wu Q; Zhu W; He Y; Huang Y
    Front Pharmacol; 2022; 13():1019826. PubMed ID: 36386191
    [No Abstract]   [Full Text] [Related]  

  • 4. First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a China-based cost-effectiveness analysis.
    Yi L; Zhou Z; Zeng X; Tan C; Liu Q
    Front Immunol; 2024; 15():1408928. PubMed ID: 39035009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Wang J; Zhou C; Yao W; Wang Q; Min X; Chen G; Xu X; Li X; Xu F; Fang Y; Yang R; Yu G; Gong Y; Zhao J; Fan Y; Liu Q; Cao L; Yao Y; Liu Y; Li X; Wu J; He Z; Lu K; Jiang L; Hu C; Zhao W; Zhang B; Shi W; Zhang X; Cheng Y;
    Lancet Oncol; 2022 Jun; 23(6):739-747. PubMed ID: 35576956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective.
    Tong YH; Ding HY; Xin WX; Zhong LK; Xu GQ; Zhang B; Yang GN; Fang L
    Tumori; 2022 Feb; 108(1):33-39. PubMed ID: 33511911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis.
    Lin S; Luo S; Gu D; Li M; Rao X; Wang C; Huang P; Xu X; Weng X
    Oncologist; 2021 Nov; 26(11):e2013-e2020. PubMed ID: 34431578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated cost-effectiveness analysis of adebrelimab plus chemotherapy for extensive-stage small cell lung cancer in China.
    Long Y; Wang H; Xie X; Li J; Xu Y; Zhou Y
    BMJ Open; 2024 Apr; 14(4):e077090. PubMed ID: 38582540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing.
    Shao T; Zhao M; Liang L; Tang W
    BioDrugs; 2023 May; 37(3):421-432. PubMed ID: 36840914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review.
    Wang T; Li Y; Zheng X
    BMC Health Serv Res; 2023 Jun; 23(1):691. PubMed ID: 37365540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
    Liu Q; Tan C; Yi L; Wan X; Peng L; Li J; Luo X; Zeng X
    PLoS One; 2021; 16(11):e0258605. PubMed ID: 34780478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small-cell lung cancer (ES-SCLC): a phase II trial.
    Chen D; Zou B; Li B; Gao A; Huang W; Shao Q; Meng X; Zhang P; Tang X; Hu X; Zhang Y; Guo J; Zhao C; Yuan J; Li Q; Zhu C; Yu J; Wang L
    EClinicalMedicine; 2024 Sep; 75():102795. PubMed ID: 39252865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis.
    Zhu Y; Hu H; Ding D; Li S; Liao M; Shi Y; Huang J
    Cost Eff Resour Alloc; 2021 Dec; 19(1):77. PubMed ID: 34863203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data.
    Wang BC; Fu C; Lin GH
    Front Immunol; 2023; 14():1185577. PubMed ID: 37215120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of durvalumab, tremelimumab, and etoposide-platinum in first-line treatment of extensive-stage small cell lung cancer.
    Meng M; Liu X; Liang X; Chen X; Li Y
    Medicine (Baltimore); 2024 Apr; 103(16):e37836. PubMed ID: 38640325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-Line Chemo-Immunotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness Analysis.
    Liu Q; Luo X; Yi L; Zeng X; Tan C
    Front Oncol; 2021; 11():699781. PubMed ID: 34268124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China.
    Lang W; Ai Q; He Y; Pan Y; Jiang Q; Ouyang M; Sun T
    Int J Clin Pharm; 2024 Dec; 46(6):1536-1545. PubMed ID: 39276261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-Line Treatments for Extensive-Stage Small-Cell Lung Cancer With Immune Checkpoint Inhibitors Plus Chemotherapy: A Network Meta-Analysis and Cost-Effectiveness Analysis.
    Kang S; Wang X; Zhang Y; Zhang B; Shang F; Guo W
    Front Oncol; 2021; 11():740091. PubMed ID: 35127468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer.
    Liang X; Chen X; Li H; Li Y
    Front Public Health; 2023; 11():1156427. PubMed ID: 37727602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.
    Luo X; Zhou Z; Zeng X; Liu Q
    Front Pharmacol; 2022; 13():935581. PubMed ID: 35935852
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.